Santé

Groupe Mutuel Might Leave Santésuisse
Groupe Mutuel's CEO Thomas Boyer discusses the possibility of leaving Santésuisse, advocating for unity in health associations for the benefit of premium payers.
Helpany Expands to the USA: A New Chapter in Senior Care Innovation
Swiss startup Helpany sets its sights on the US, bringing its advanced AI-driven senior care solution to new markets in Spring 2024.
Zurich Research AI
Zurich Research AI: Detects Heart Defects
Zurich researchers develop AI to spot pulmonary hypertension in newborns, offering hope for early diagnosis and improved outcomes.
Sandoz prévoit une croissance et une augmentation des marges en 2024
Sandoz, désormais une entité indépendante, célèbre une année de croissance et vise des ventes et des marges accrues pour 2024.
Fuite de gaz naturel à Rotkreuz ZG : 15 habitants évacués
À Rotkreuz ZG, une fuite de gaz consécutive à un accident de forage a entraîné une évacuation rapide.
Digitalising Healthcare
Switzerland Will Spend CHF 400 Million on Digitalising Healthcare
Switzerland's National Council greenlights the CHF 400 million Digisanté program to advance healthcare digitalisation, amid calls for vigilant oversight.
Alcon
Alcon vise un chiffre d'affaires de $12 milliards d'ici 2027
Alcon aims for growth with a $12 billion revenue target by 2027, post-Novartis spin-off.
Swiss Health Care Sector Shortage: Spitex Launch Campaign
Switzerland faces a critical healthcare worker shortfall, with an urgent need for new entrants, spurring nationwide recruitment efforts.
Zambon Group
Zambon Group: Exclusive Licensing Deal for IPX203 in Europe
Keystone/SDA - DARRON CUMMINGS Amneal Pharmaceuticals, aligning with Zambon Group, announces an exclusive licensing pact for IPX203 in key European regions.
Swiss biotech
Idorsia, entreprise suisse de biotechnologie : l'action s'envole - mais pourquoi ?
Idorsia's Surging Stock: Speculations Amid Silence Keystone/SDA - GEORGIOS KEFALAS Swiss biotech firm Idorsia, based in Basel, has seen a spike in stock prices from just $2.
Le CSEM s'associe à ClexBio pour lutter contre les problèmes cardiovasculaires
Le CSEM s'associe à l'innovateur nordique ClexBio pour mettre au point un bioréacteur, un saut dans les veines humaines cultivées en laboratoire pour la médecine régénérative.
Social Democrats Health Insurance Initiative Fails
Swiss Center Rejects Health Premium Cap Proposal, Debates Cost and Solidarity in Healthcare Keystone/SDA - PETER SCHNEIDER The Center rejects the SP's premium relief initiative.
Alys Pharmaceuticals se lance avec $100M de Medicxi
Alys Pharmaceuticals, the immuno-dermatology trailblazer with a $100M boost from Medicxi.
Swissmedic
Swissmedic Approves New Drugs Against Cancer
Swissmedic's latest approvals spotlight oncology with ten new cancer drugs leading the charge.
Swiss Breakthrough: Halting Ageing in Mice with Novel Drug
Swiss researchers achieve a milestone in anti-ageing research by successfully slowing down the ageing process in mice, opening new avenues for human health advancements.
Avertissement public : Résidus de pesticides dans les tomates séchées de Ceposa AG
Ceposa AG découvre un pesticide nocif, le chlorpyrifos-éthyl, dans des tomates séchées, ce qui présente des risques potentiels pour la santé.
Fribourg Cantonal Hospital Receives 175M CHF from the State
The Fribourg Cantonal Hospital is set for a financial revival with a 175 million francs boost from the state, marking a significant step towards addressing its prolonged financial woes.
New Slimming Products Could Drive Costs up in the Healthcare Sector
GLP-1 Drugs: A Costly Revolution in Obesity Treatment. Drugs with a punch like the new GLP-1 drugs inevitably lead to discussions about their cost.

Articles connexes

Rester en contact

À noter

the swiss times
Une production de UltraSwiss AG, 6340 Baar, Suisse
Copyright © 2024 UltraSwiss AG 2024 Tous droits réservés